Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Checked against the public recordLast updated Sep 21, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Fate Therapeutics
- Interventions being studied
- Genetic: Allogeneic natural killer (NK) cell
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study * Subjects who have provided Informed consent prior to their study participation Exclusion Criteria: * Not Applicable
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UCSD Moores Cancer CenterSan Diego, California
- University of Minnesota Masonic Cancer CenterMinneapolis, Minnesota
- Hackensack University Medical CenterHackensack, New Jersey
- MD Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 21, 2023. Always confirm current availability with the study team.